Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 794 across all filing types
Latest filing 2020-10-07 Regulatory Filings
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2020-10-07 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the issuance and allotment of shares pursuant to a Scheme of Arrangement (demerger) approved by the National Company Law Tribunal. It details the share issuance and allotment to shareholders and mentions listing on stock exchanges subject to approvals. The document is a regulatory announcement about capital structure changes following a corporate restructuring, not a full financial report or detailed presentation. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about share allotment. The content fits best under Capital/Financing Update (CAP) as it concerns issuance and allotment of shares following a scheme of arrangement.
2020-10-06 English
Trading Window
Regulatory Filings Classification · 100% confidence The document contains only an omitted picture placeholder and has a true length of 53 characters, indicating it is extremely short and contains no substantive content or financial data. It does not provide any report, announcement, or detailed information. Given the lack of content, it cannot be classified as any specific report or announcement type. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2020-09-30 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a Warning Letter received from the USFDA about a pharmaceutical facility owned by the company's subsidiary. It discusses regulatory compliance and the company's response to the warning letter. The document is a clarification/confirmation on a news item and does not contain financial statements, earnings data, or detailed report content. It is a regulatory communication related to compliance and regulatory matters, not a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is a direct communication to the exchange, not a report publication announcement or a full report.
2020-09-30 English
Press Release
Regulatory Filings
2020-09-24 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-09-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.